The present invention provides novel methods for the detection of antibodies, in particular, blood group antibodies. The methods of this invention may be applied to pre-transfusion blood compatibility testing for the detection of incompatibility between donor units (comprising donor red blood cells (erythrocytes)) and a recipient.

A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.

A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.

Method and corresponding detection unit to detect bacterial activity in a biological sample, in particular, but not only, blood samples contained in a test tube with a stopper.

Method and corresponding detection unit to detect bacterial activity in a biological sample, in particular, but not only, blood samples contained in a test tube with a stopper.

The invention relates to methods and systems for removal of pathogens from blood or blood products. The invention further relates to methods and systems for treatment and diagnosis of infection in the blood and/or sepsis in a patient in need thereof.

A facile laboratory-based method and kit for use in accordance with the method is disclosed. The method allows for the localisation of biomolecules comprising a conjugatable sulfhydryl group to be localised to the surface of cells, such as red blood cells, as lipid conjugates. The method obviates the need to purify the lipid-conjugated biomolecule before contacting with the cells.

A facile laboratory-based method and kit for use in accordance with the method is disclosed. The method allows for the localisation of biomolecules comprising a conjugatable sulfhydryl group to be localised to the surface of cells, such as red blood cells, as lipid conjugates. The method obviates the need to purify the lipid-conjugated biomolecule before contacting with the cells.

Disclosed are systems and methods for detecting extracellular ligands. The disclosed systems and method for detecting extracellular ligands typically comprise or utilize engineered red blood cells (eRBCs) that comprises modular extracellular sensors. The eRBCs may comprise: (i) a first exogenous extracellular sensor; the first extracellular sensor comprising: a) a ligand binding domain, b) a transmembrane domain, and c) a first fragment of a functional protein, and (ii) a second exogenous extracellular sensor; the second extracellular sensor comprising: a) a ligand binding domain, b) a transmembrane domain, and c) a second fragment of the functional protein. In the eRBCs, the ligand binding domain of the first exogenous sensor and the ligand binding domain of the second exogenous sensor bind to the same ligand to form a ternary complex, and the first fragment of the functional protein and the second fragment of the functional protein interact in the ternary complex to reconstitute functional activity of the functional protein.

Disclosed are systems and methods for detecting extracellular ligands. The disclosed systems and method for detecting extracellular ligands typically comprise or utilize engineered red blood cells (eRBCs) that comprises modular extracellular sensors. The eRBCs may comprise: (i) a first exogenous extracellular sensor; the first extracellular sensor comprising: a) a ligand binding domain, b) a transmembrane domain, and c) a first fragment of a functional protein, and (ii) a second exogenous extracellular sensor; the second extracellular sensor comprising: a) a ligand binding domain, b) a transmembrane domain, and c) a second fragment of the functional protein. In the eRBCs, the ligand binding domain of the first exogenous sensor and the ligand binding domain of the second exogenous sensor bind to the same ligand to form a ternary complex, and the first fragment of the functional protein and the second fragment of the functional protein interact in the ternary complex to reconstitute functional activity of the functional protein.